Evidence map›Paper›PMID 42458172›Full record

Trial reportBrain topography2026

Dopaminergic Drugs Modulate Resting-State EEG Microstates in Healthy Participants.

Renate de Bock, Amatya J Mackintosh, Alexandra Korda, Alina Preuss, Daniel J Hauke, Andreea O Diaconescu, Philipp Sterzer, Stefan Borgwardt, Christina Andreou

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Brain topography, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Renate de BockDepartment of Psychiatry (UPK), University of Basel, Wilhelm Klein-Strasse 27, Basel, 4002, Switzerland. renate.debock@unibas.ch.ORCID http://orcid.org/0000-0003-3774-2086
Amatya J MackintoshFaculty of Psychology, Department Clinical Psychology and Epidemiology, Missionsstrasse 62a, Basel, 4055, Switzerland.ORCID http://orcid.org/0000-0002-4535-8829
Alexandra KordaTranslational Psychiatry, Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.ORCID http://orcid.org/0000-0001-8843-4951
Alina PreussTranslational Psychiatry, Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.ORCID http://orcid.org/0009-0004-4254-7247
Daniel J HaukeHawkes Institute, Department of Computer Science, University College London, 90 High Holborn, London, WC1V6LJ, UK.ORCID http://orcid.org/0000-0003-1772-9239
Andreea O DiaconescuKrembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, 250 College St, Toronto, ON, M5T1R8, Canada.ORCID http://orcid.org/0000-0002-3633-9757
Philipp SterzerDepartment of Psychiatry (UPK), University of Basel, Wilhelm Klein-Strasse 27, Basel, 4002, Switzerland.ORCID http://orcid.org/0000-0003-4687-2317
Stefan BorgwardtTranslational Psychiatry, Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.ORCID http://orcid.org/0000-0002-5792-3987
Christina AndreouTranslational Psychiatry, Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.ORCID http://orcid.org/0000-0002-6656-9043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Changes in the temporal parameters of EEG microstates are observed in various psychiatric illnesses, including psychotic disorders. These changes have also been observed in individuals with a clinical or genetic high risk for psychosis. It is unclear whether dopamine abnormalities, distinctive of psychotic disorders, contribute to microstate alterations. Fifty-eight healthy participants (M: F = 32:26) took part in a single-dose drug challenge study. Using a randomized, double-blind, cross-over, and placebo-controlled design, participants received the dopamine precursor L-DOPA (100 mg), the dopamine antagonist haloperidol (2 mg), and a placebo. Resting-state (10 min, eyes-closed) 64-channel EEG was recorded at peak drug effects. We calculated temporal parameters (coverage, duration, and occurrence) of 5 microstate classes (A-E) and compared them between drug conditions using linear mixed-effect models. Significant group x class interactions were observed for all parameters. Compared to placebo, parameters of microstate B were decreased under L-DOPA (duration and occurrence) and haloperidol (coverage, duration, and occurrence). Coverage and occurrence of microstate C were reduced under L-DOPA compared to haloperidol and placebo. Parameters of microstate E were reduced under L-DOPA compared to haloperidol (coverage and occurrence) and placebo (coverage, duration, and occurrence). Both haloperidol and L-DOPA increased all parameters of microstate D, compared to placebo. Our results show that resting-state EEG microstates are modulated by dopaminergic drugs. However, extrapolations from healthy controls to patients with psychotic disorders are complicated by various factors. Further studies should investigate the (long-term) effects of haloperidol and other antipsychotics on EEG microstates in patients with psychotic disorders.

Indexed as

BrainDopamine AgentsElectroencephalographyHaloperidolLevodopaAdultCross-Over StudiesDopamine AntagonistsDouble-Blind MethodFemaleHumansMaleRestYoung AdultDopamine AgentsDopamine AntagonistsHaloperidolLevodopaDopamineEEG microstatesElectroencephalogramHaloperidolL-DOPAResting-state

Identifiers

PMID42458172
PMCPMC13373011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.